August 29, 2016 — SynCardia Systems, manufacturer of the Total Artificial Heart (TAH), announced that the judge ...
The American Medical Society for Sports Medicine (AMSSM) last week released a new position statement on cardiovascular pre-participation screening for athletes. The statement discusses current evidence and knowledge gaps while offering recommendations and future directions.
September 12, 2016 — Vivasure Medical announced last week that the company has completed a Series C financing of €16.2M ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
A Saint Louis University researcher has received a grant to study the effects of treating post-traumatic stress disorder (PTSD) on cardiovascular and metabolic health. Jeffrey Scherrer, Ph.D., associate professor in Family and Community Medicine, received $2,348,320 from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH).
Veniti Inc. has closed on $25 million in Series D equity financing from Boston Scientific Corp. The funds will allow Veniti to complete the VIRTUS Trial and regulatory filing for the Vici Venous Stent System. The trial is being performed under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE). The company also intends to expand product development and commercial operations.
September 9, 2016 — New research published Sept. 8 in the Open Access journal PLOS Biology reports the role of genes in ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL study has been carried out. The implantation was conducted in accordance with the authorizations obtained from the ANSM (French national agency for the safety of medicines and health products) and CPP (patient protection committee).
Six-month preclinical data from trials of a Xeltis bioabsorbable aortic conduit were presented at the 2016 scientific meeting of the International Society for Applied Cardiovascular Biology (ISACB). The data was presented by Prof. Frederick Schoen, M.D., Ph.D., senior pathologist and executive vice chairman, Department of Pathology at Brigham and Women’s Hospital, and professor of pathology and health sciences and technology, Harvard Medical School.
September 8, 2016 — Prevencio Inc. announced that data on its new clinical and multi-protein panel to diagnose ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Technological and administrative obstacles are significantly cutting into available time for physicians to engage with patients. Nearly half a physician’s office day is now filled by data entry into electronic medical records (EHRs) and administrative desk work, according to a new time-motion study conducted by experts at the American Medical Association (AMA) and Dartmouth-Hitchcock healthcare system. The study results were published in the Annals of Internal Medicine.
September 7, 2016 — Toshiba America Medical Systems Inc. announced that its Aplio 500 Platinum ultrasound system will be ...
September 7, 2016 — St. Jude Medical Inc. (SJM) has filed a lawsuit against Muddy Waters Consulting LLC, Muddy Waters ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
With any new system implementation in a healthcare system, there is a fear of downtime and potential adverse impact on ...
September 5, 2016 — Lombard Medical Inc., a company focused on endovascular aneurysm repair (EVAR) of abdominal aortic ...
St. Jude Medical Inc. announced the start of the St. Jude Medical Amplatzer Amulet IDE trial of the company’s Amplatzer Amulet Left Atrial Appendage (LAA) Occluder. The trial will evaluate the safety and effectiveness of the device, used to close the LAA in patients diagnosed with non-valvular atrial fibrillation (AF). The first implant of the study took place at North Mississippi Medical Center in Tupelo, Miss., by Jim Stone, M.D.